Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Issued (2022 - 2025)

Historic Shares Issued for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $115000.0.

  • Zentalis Pharmaceuticals' Shares Issued rose 2500.0% to $115000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $304000.0, marking a year-over-year decrease of 1289.4%. This contributed to the annual value of $349000.0 for FY2024, which is 9985.19% down from last year.
  • Zentalis Pharmaceuticals' Shares Issued amounted to $115000.0 in Q3 2025, which was up 2500.0% from $189000.0 recorded in Q1 2025.
  • Zentalis Pharmaceuticals' Shares Issued's 5-year high stood at $235.3 million during Q2 2023, with a 5-year trough of $9000.0 in Q2 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Shares Issued value was $310500.0 (recorded in 2023), while the average stood at $47.1 million.
  • In the last 5 years, Zentalis Pharmaceuticals' Shares Issued skyrocketed by 2767.81% in 2023 and then plummeted by 9999.62% in 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' Shares Issued (Quarter) stood at $48.6 million in 2022, then skyrocketed by 383.92% to $235.3 million in 2023, then plummeted by 99.96% to $92000.0 in 2024, then increased by 25.0% to $115000.0 in 2025.
  • Its Shares Issued was $115000.0 in Q3 2025, compared to $189000.0 in Q1 2025 and $92000.0 in Q3 2024.